Once Scorned, Orphan Diseases Have Become Popular
Companies developing drugs for Orphan Disease have emerged as a specialty group within the Biotechnology industry. These companies are using provisions of the 1984 Orphan Drug Legislation that provide FDA assistance, financial and tax incentives, and favorable reimbursement. During the first 15 years after the legislation, Orphan Drug approvals increased attention to rare diseases and led to a few successful product introductions. There have been some outstanding successes, leading more companies to focus on orphan drugs. However, we believe this overlooks the difficulties involved in rare diseases.
The business model for an Orphan Drug company was largely pioneered by Genzyme in 1990s, which demonstrated that rare diseases could lead to profitable products. At...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|